\u00abReduction of autism symptoms after bacterial microbiota transplantation\u00bb is a study published in 2012 by the research team of Finegold et al.<\/strong>. This study was a randomized controlled clinical trial (RCT) that evaluated the effect of microbiota transplantation in children with autism. The study included children with autism who had gastrointestinal symptoms and also had a high load of Clostridium bolteae and Clostridium perfringens in their feces. Participants were randomized to receive a microbiota transplant or a placebo. The researchers evaluated changes in autism symptoms and in the recipient's microbiota before and after transplantation. The results of the study showed that children who received the microbiota transplant experienced a greater reduction in autism symptoms compared to those who received the placebo. <\/p>\n\n\n\n

The researchers also observed changes in the recipient's microbiota after transplantation. "A randomized, placebo-controlled trial of oral vancomycin to treat regressive-onset autism" (2012)<\/strong>: This study evaluated the effect of oral administration of vancomycin, an antibiotic, in children with autism spectrum disorder (ASD) and gastrointestinal symptoms. Participants were randomly assigned to receive either vancomycin or a placebo over a 12-week time period. The investigators evaluated gastrointestinal and ASD symptoms before and after treatment. The results suggested that vancomycin may improve certain gastrointestinal and ASD symptoms in these children. <\/p>\n\n\n\n

\u00abGut microbiota in children with autism spectrum disorders: Profiles by symptom severity and parental report of psychiatric symptoms\u00bb (2018)<\/strong>: This study compared the gut microbiota of children with ASD with different levels of symptom severity and with parents who reported psychiatric symptoms. The researchers took stool samples from the participants and analyzed the composition of the bacteria present. They also assessed the parents' ASD symptoms and psychiatric symptoms. The results suggested that the microbiota may be associated with the severity of ASD symptoms and with psychiatric symptoms in parents. "Fecal microbiota transplantation for the treatment of autism spectrum disorder: A systematic review" is a systematic review published in 2017 by the research team of Maziarz et al. In this review, the authors examined the evidence available to date on the use of microbiota transplantation as a treatment for autism spectrum disorder (ASD). The authors included in the review three studies that evaluated the effect of microbiota transplantation in people with ASD. The results of the studies showed an improvement in ASD symptoms after microbiota transplantation, but adverse effects were also observed in some participants. The authors concluded that, although the available studies suggest that microbiota transplantation may have a beneficial effect on some ASD symptoms, further research of higher quality and with a larger sample size is still needed to fully assess the safety and effectiveness of transplantation. microbiota as a treatment for ASD. <\/p>\n\n\n\n

\u00abAutism-associated gut microbiome differentiates children from controls and associates with social behavior\u00bb (2017)<\/strong>: This study compared the gut microbiota of children with autism spectrum disorder (ASD) and children without the disorder. The researchers took stool samples from the participants and analyzed the composition of the bacteria present. They found that there were significant differences in the composition of the microbiota between the two groups. In addition, an association was observed between certain characteristics of the microbiota and social behaviors in children with ASD. <\/p>\n\n\n\n

\u00abIntranasal administration of Lactobacillus reuteri as a treatment for children with autism spectrum disorder: a randomized clinical trial\u00bb (2018)<\/strong>: This study evaluated the effect of nasal administration of Lactobacillus reuteri, a health-promoting bacterium, in children with ASD. Participants were randomly assigned to receive L. reuteri or a placebo over a period of eight weeks. The results suggested that the administration of L. reuteri may be an effective treatment option to improve certain symptoms of ASD, such as communication and socialization. <\/p>\n\n\n\n

\u00abLong-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota\u00bb (2019)<\/strong>: This study explored the long-term effect of microbiota transfer therapy (MTT) in people with ASD. Study participants received a course of MTT, which consisted of the ingestion of a fecal microbiota supplement over a period of six weeks. After completing the MTT course, the participants were followed for an additional 12-week period. The results suggested that MTT may be effective in improving ASD symptoms and gut microbiota in the long term. <\/p>\n\n\n\n

\u00abMicrobiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study\u00bb (2019)<\/strong>: This study evaluated the effect of MTT in children with ASD. Participants received a course of MTT, and researchers assessed gastrointestinal and ASD symptoms before and after treatment. The results suggested that MTT may improve gastrointestinal and ASD symptoms in these children. <\/p>\n\n\n\n